Search results
Showing 2641 to 2655 of 8238 results
Belzutifan for treating advanced pheochromocytoma or paraganglioma [TSID12304]
Awaiting development Reference number: GID-TA11928 Expected publication date: TBC
In development Reference number: GID-TA11636 Expected publication date: 26 August 2026
Artificial intelligence (AI) technologies to help detect prostate cancer on multiparametric (mp) MRI
In development Reference number: GID-HTE10089 Expected publication date: TBC
In development Reference number: GID-HTE10079 Expected publication date: TBC
Riliprubart for treating chronic inflammatory demyelinating polyneuropathy [TSID12314]
Awaiting development Reference number: GID-TA11917 Expected publication date: TBC
Awaiting development Reference number: GID-TA11932 Expected publication date: TBC
Awaiting development Reference number: GID-TA11933 Expected publication date: TBC
ID6611 Obesity, overweight - semaglutide (including review of TA875)
Awaiting development Reference number: GID-TA11851 Expected publication date: TBC
In development Reference number: GID-HTE10067 Expected publication date: 19 May 2026
In development Reference number: GID-TA10239 Expected publication date: 06 August 2026
Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people 1 year and over ID6400
Awaiting development Reference number: GID-TA11509 Expected publication date: TBC
Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)
Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making
Chronic anal fissure: botulinum toxin type A injection (ESUOM14)
Summary of the evidence on botulinum toxin type A injection for treating chronic anal fissure to inform local NHS planning and decision-making
Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making
Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)
Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making